SYC-1456 (developed by us) can suppress onco-MLL1 mediated aberrant gene expression, induce cell differentiation and apoptosis, and inhibit tumor growth in cell and mouse models of MLL1-r leukemia, thereby validating ENL inhibition is a viable therapeutic approach [22]. The gene discussed is KMT2A; the disease is neoplasm.